Overview of Renal Cell Carcinoma (RCC)

Opinion
Video

Thomas Hutson, DO, PharmD, discusses renal cell carcinoma, including its epidemiology, risk factors, subtypes, and management approaches, in a dialogue with his clinical nurse, Kacie Ellis, RN, and his patient, Mr. Cesar Fuentes.

Recent Videos
A review of patients with metastatic clear cell renal cell carcinoma shows radiological tumor burden as an independent prognostic factor for survival.
A phase 2 trial is assessing ubamatamab in patients with MUC16-expressing SMARCB1-deficient renal medullary carcinoma and epithelioid sarcoma.
Analysis of 2 phase 1 trials compared gut biome diversity between standard of care with or without CBM588 in patients with metastatic renal cell carcinoma.
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Rohit Gosain, MD; Sumanta Kumar Pal, MD, FASCO; and Rahul Gosain, MD, presenting slides
Related Content
Phase 3 data support benmelstobart/anlotinib as a new potential standard in the frontline treatment of patients with advanced renal cell carcinoma.

Benmelstobart Combo Improves Outcomes Vs Sunitinib in Advanced RCC

Kyle Doherty
September 19th 2024
Article

Phase 3 data support benmelstobart/anlotinib as a new potential standard in the frontline treatment of patients with advanced renal cell carcinoma.

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Exploring New Possibilities in Kidney Cancer Detection and Therapy

Karl Semaan, MD, MSc ;Neil J. Shah, MBBS;Bradley McGregor, MD
July 22nd 2024
Podcast

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Data from LITESPARK-005 establish belzutifan as a treatment option in advanced RCC following prior immune checkpoint and antiangiogenic therapies.

Belzutifan Significantly Improves PFS Vs Everolimus in Clear Cell RCC

Russ Conroy
September 4th 2024
Article

Data from LITESPARK-005 establish belzutifan as a treatment option in advanced RCC following prior immune checkpoint and antiangiogenic therapies.

Santosh Rao, MD, discusses the formation of new guidelines informing the use of integrative oncology for patients with kidney cancer from the Society for Integrative Oncology.

Oncology On-The-Go Podcast: Integrative and Palliative Kidney Cancer Care

Santosh Rao, MD
March 28th 2023
Podcast

Santosh Rao, MD, discusses the formation of new guidelines informing the use of integrative oncology for patients with kidney cancer from the Society for Integrative Oncology.

Belzutifan Improves PFS Across Subgroups for Advanced ccRCC

Belzutifan Improves PFS Across Subgroups for Advanced ccRCC

Ashling Wahner
July 12th 2024
Article

“In LITESPARK-005, PFS and response rates favored belzutifan vs everolimus across [several patient subgroups, including] IMDC risk, number of prior lines [of therapy], and number of prior VEGF TKIs, specifically,” said Laurence Albiges, MD, PhD.

Efficacy Highlighted in Fianlimab/Cemiplimab in Pretreated Advanced ccRCC

Efficacy Highlighted in Fianlimab/Cemiplimab in Pretreated Advanced ccRCC

Chris Ryan
July 12th 2024
Article

“These data support the development of fianlimab plus cemiplimab combination therapy for patients with metastatic ccRCC,” said Miso Kim, MD, PhD.